Publications by authors named "Joshua D Brody"

Claim this Profile
R
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.
Taylor R Brooks, Emily C Zabor, Yohanna B Bedelu, Xi Yang, Yasmin H Karimi, Joshua D Brody

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.
Mikhail Roshal, Isabella Y Kong, Wikum Dinalankara, Jonathan B Reichel, Matthew Teater, Joshua D Brody

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potentiating CAR-T bystander killing by enhanced Fas/FasL signaling mitigates antigen escape in heterogeneous tumors.
Matthew J Lin, Joanna K Chorazeczewski, Gvantsa Pantsulaia, Alan Cooper, Moah Sohn, Joshua D Brody

bioRxiv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.
Kevin J Harrington, Stephane Champiat, Joshua D Brody, Byoung Chul Cho, Emanuela Romano

Clin Cancer Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Therapy of CAR+ T-Cell Lymphoma after Anti-BCMA CAR T-Cell Therapy.
Adolfo Aleman, Oliver Van Oekelen, David T Melnekoff, Leah Grossman, Tarek H Mouhieddine, Joshua D Brody

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer vaccines and the future of immunotherapy.
Orrin Pail, Matthew J Lin, Theodora Anagnostou, Brian D Brown, Joshua D Brody

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing antitumor immunity through chemotherapeutic-derived lipid nanoparticle-induced immunogenic cell death and CD40L/Flt3L mRNA-mediated dendritic cell activation.
Xucheng Hou, Chang Wang, Yichen Zhong, Leiming Wang, Diana D Kang, Joshua D Brody

J Control Release· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed/refractory large B-cell lymphoma.
Lorenzo Falchi, Martin Hutchings, Carmelo Carlo-Stella, Franck Morschhauser, Michael Dickinson, Joshua D Brody

Haematologica· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Joshua D Brody, Judit Jørgensen, David Belada, Régis Costello, Marek Trněný

Blood· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.
Danilo Fiore, Luca Vincenzo Cappelli, Liu Zhaoqi, Nikita Kotlov, Maria Sorokina, Joshua D Brody

Cell Rep Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.
Zachary S Morris, Sandra Demaria, Arta M Monjazeb, Silvia C Formenti, Ralph R Weichselbaum, Joshua D Brody

Lancet Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer.
Raphaël Mattiuz, Jesse Boumelha, Pauline Hamon, Jessica Le Berichel, Abishek Vaidya, Joshua D Brody

bioRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bispecific antibody targeting of lipid nanoparticles.
Angelo Amabile, Matthew Phelan, Zhixin Yu, Pedro Silva, Adam Marks, Joshua D Brody

bioRxiv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, Aby Buchbinder, Marc Buyse

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors.
Anthony W Tolcher, Joshua D Brody, Nishanthan Rajakumaraswamy, Michelle Kuhne, Torsten Trowe

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Pier Luigi Zinzani, Gilles Salles, Alison J Moskowitz, Armando Santoro, Amitkumar Mehta, Joshua D Brody

Blood Adv· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
Jason J Luke, Diwakar Davar, Robert H Andtbacka, Nina Bhardwaj, Joshua D Brody

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell States, Repertoire, and Function in Classical Hodgkin Lymphoma Revealed through Single-Cell Analyses.
Xiufen Chen, Jovian Yu, Girish Venkataraman, Sonali M Smith, Mengjie Chen, Joshua D Brody

Cancer Immunol Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
Sarah Aminov, Orsi Giricz, David T Melnekoff, R Alejandro Sica, Veronika Polishchuk, Joshua D Brody

J Clin Invest· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin as a bridge to combination chemotherapy in gray zone lymphoma with severe liver impairment: a case report.
Roshan Asrani, Turgot Bora Cengiz, Bruce E Petersen, Theodora Anagnostou, Joshua D Brody

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th-December 1st, 2022).
Paolo A Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D Brody

J Transl Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pattern recognition receptor agonists in pathogen vaccines mediate antitumor T-cell cross-priming.
Mark Aleynick, Judit Svensson-Arvelund, Gvantsa Pantsulaia, Kristy Kim, Samuel A Rose, Joshua D Brody

J Immunother Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study.
John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H Moskowitz, Joshua D Brody

Leuk Lymphoma· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.
Judit Svensson-Arvelund, Sara Cuadrado-Castano, Gvantsa Pantsulaia, Kristy Kim, Mark Aleynick, Joshua D Brody

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In CAR T cell-treated lymphomas, the T cell rich get richer.
Theodora Anagnostou, Joshua D Brody

Nat Med· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis